EXACT THERAPEUTICS ANNOUNCES GRANTING OF PATENT IN JAPAN FOR ACOUSTIC CLUSTER THERAPY
OSLO/LONDON, MAY 19th 2021
EXACT THERAPEUTICS AS (“EXACT-Tx” or the “Company”), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announced that it has been granted a patent for its innovative Acoustic Cluster Therapy® technology in Japan.
The patent covers EXACT-Tx`s unique microbubble/microdroplet formulation and its use, co-administered with a range of pharmaceutical agents for ultrasound mediated therapeutic targeting.
“We are delighted with the decision of the Japanese Patent Office in granting this important patent for ACT®, which complements the existing patent granted in China in November 2019. This core patent represents the foundation of our dynamic IP strategy, which encompasses the use of ACT® with a variety of therapeutics across a multitude of indications”,
said Dr Rafiq Hasan, CEO of EXACT Therapeutics AS.
About EXACT
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com
For more information contact:
Dr Rafiq Hasan
CEO EXACT Therapeutics
Rafiq@exact-tx.com